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Abstract
Background: There are several proven therapies for patients with ischemic stroke or transient
ischemic attack (TIA), including prophylaxis of deep venous thrombosis (DVT) and initiation of
antithrombotic medications within 48 h and at discharge. Stroke registries have been promoted as
a means of increasing use of such interventions, which are currently underutilized.
Methods: From 1999 through 2003, 86 U.S. hospitals participated in Ethos, a voluntary web-based
acute stroke treatment registry. Detailed data were collected on all patients admitted with a
diagnosis of TIA or ischemic stroke. Rates of optimal treatment (defined as either receipt or a valid
contraindication) were examined within each hospital as a function of its length of time in registry.
Generalized estimating equations were used to adjust for patient and hospital characteristics.
Results: A total of 16,301 patients were discharged with a diagnosis of stroke or TIA from 50
hospitals that participated for more than 1 year. Rates of optimal treatment during the first 3
months of participation were as follows: 92.5% for antithrombotic medication within 48 h, 84.6%
for antithrombotic medications at discharge, and 77.1% for DVT prophylaxis. Rates for all
treatments improved with duration of participation in the registry (p < 0.05), with the most
dramatic improvements in the first year.
Conclusion: In a large cohort of patients with stroke or TIA, three targeted quality-improvement
measures improved among hospitals participating in a disease-specific registry. Although the
changes could be attributed to interventions other than the registry, these findings demonstrate
the potential for hospital-level interventions to improve care for patients with stroke and TIA.
Background
There are several therapies for patients with ischemic
stroke that have been proven in clinical trials and are rec-
ommended widely in consensus guidelines [1-3]. These
include prophylaxis for deep venous thrombosis (DVT)
[4], antithrombotic therapy within 48 hours [5], and anti-
thrombotic therapy at discharge [6]. Nationally represent-
ative data from a sample of patients discharged with
ischemic stroke who utilized Medicare benefits demon-
strated underutilization of antithrombotic medications at
discharge, with 17% without a contraindication failing to
receive them [7]. Nationally representative data on use of
antithrombotic medications within 48 hours of admis-
sion and on use of DVT prophylaxis are lacking and would
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be useful as benchmarks for quality-improvement initia-
tives.
Registries have been used as tools to define deficiencies
and improve quality of care. They are meant to enlighten
practitioners and administrators about deficiencies, moti-
vate change, and direct efforts [8]. When used as part of a
continuous quality improvement program that includes
institutional and practitioner-level feedback, registries
have been demonstrated to improve care [9].
Several organizations have promoted formation of stroke
registries to improve quality of care [10-13], and the Joint
Commission on the Accreditation of Healthcare Organi-
zations (JCAHO) requires maintenance of a registry to
track quality-of-care indicators as part of its added certifi-
cation for primary stroke centers [14]. We previously
showed that quality of care improved for patients with
stroke treated at six hospitals in California that imple-
mented standardized stroke orders and tracked processes
of care in a registry [15]. Using a national acute stroke reg-
istry, we sought to establish benchmarks for three quality
improvement indicators recommended by the JCAHO –
DVT prophylaxis and prescription for antithrombotic
medications within 48 hours of admission and at hospital
discharge – among patients with ischemic stroke or TIA
admitted to a large sample of hospitals in the U.S. We also
tested the hypothesis that duration of participation in the
registry was associated with improvement in quality of
care.
Methods
A web-based acute stroke treatment registry was created as
a tool for tracking hospital outcomes and improving qual-
ity of care (Ethos, The Stroke Group, Littleton, CO) [16].
The system allows hospital staff to capture, analyze, and
track information on care of patients seen with stroke and
TIA, and to compare results with those of other institu-
tions in the registry. Fifty standardized data elements doc-
ument aspects of acute stroke treatment, including timing
of symptom onset and arrival, diagnostic evaluation, use
of standard treatments (e.g., thrombolysis, antiplatelet
agents, anticoagulation) during hospitalization and at
discharge, documented contraindications to treatment,
and discharge disposition. Staff at each hospital can access
and update its own data at any time, and may also view
aggregated data from all other participating hospitals on a
local, state, or national level. As such, Ethos was designed
to provide data acquisition and aggregation on a large
scale and supports rapid-cycle performance improvement
[9].
Participating hospitals
Participation in Ethos is entirely voluntary and requires
payment to underwrite development and maintenance
costs. Eighty-six hospitals across the U.S. contributed to
Ethos during the study period (Figure 1). Participating
hospitals signed a contract agreeing to include all stroke
and TIA admissions in the registry throughout their
period of enrollment. Academic hospitals comprised
49%. Hospital catchment areas had a median population
of 393,496 (intra-quartile range [IQR], 223,462–
799,215). The median number of hospital beds was 326
(IQR 204–478) with a median of 275 (IQR 185–407)
stroke patients treated per year. The majority of hospitals
reported having standardized guidelines for stroke treat-
ment (98%), lab support (100%), capability of treating
acute stroke patients at all times (99%), and availability of
a neurosurgeon within 2 hours (95%). Fewer (70%)
reported the in-hospital presence of a designated stroke
team.
Data analysis
To determine whether on-going participation in the regis-
try was associated with improvement in care, we chose to
evaluate duration of a hospital's participation as a predic-
tor of 1) the receipt of antithrombotic medications within
48 hours of ED arrival, 2) prophylaxis for deep venous
thrombosis (DVT), and 3) usage of antithrombotic medi-
cations in appropriate candidates at hospital discharge.
All hospitals that remained in the Ethos registry >1 year
and contributed at least 50 patients with ischemic stroke
or TIA were included in these analyses. Duration in regis-
try was measured in months. To examine the receipt of
antithrombotic medications within 48 hours of ED arrival
and DVT prophylaxis, analyses first were performed on all
patients. Analyses then were repeated on the group of
patients who were discharged alive, to account for that
fact that some of these patients might have died before
receiving antithrombotics or DVT prophylaxis. To exam-
Distribution of the 86 hospitals participating in the registry Figure 1
Distribution of the 86 hospitals participating in the registry. 
Because of proximity, not all hospitals are visible as separate 
stars.BMC Neurology 2006, 6:20 http://www.biomedcentral.com/1471-2377/6/20
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ine usage of antithrombotic medications at hospital dis-
charge, we included only those patients who survived to
discharge. Analyses for which DVT prophylaxis was an
outcome included only ischemic stroke patients, since TIA
patients do not generally require treatment.
Optimal treatment with antithrombotic medication
within the first 48 hours of hospitalization was defined as
having received thrombolysis (intravenous or intra-arte-
rial tPA or an experimental thrombolytic), an antiplatelet
agent (defined as aspirin, clopidogrel, ticlopidine, dipyri-
damole, or extended-release dipyridamole/aspirin), or an
anticoagulant (warfarin or unfractionated or low-molecu-
lar-weight heparin), or having a valid contraindication to
antithrombotic treatment (that is, bleeding or terminal ill-
ness, as determined by documentation in the medical
records). Optimal DVT prophylaxis was defined as treat-
ment (compression boots or anticoagulation) within 48
hours or documentation that treatment was unnecessary
(such as, if the patient was ambulatory). Treatment was
assessed only in patients diagnosed with ischemic stroke,
since DVT prophylaxis is generally not necessary in
patients diagnosed with TIA.
Optimal treatment with antithrombotic medication at
discharge was defined as having received either an
antiplatelet agent or anticoagulation, or having a docu-
mented valid contraindication to antithrombotic treat-
ment. Allowable contraindications included transfer to
another facility (assuming that treatment would be pre-
scribed at the receiving facility), refusal of treatment, dis-
charge against medical advice, allergy, bleeding risk,
terminal care or illness, brain or metastatic cancer,
planned surgery, or aortic dissection. Analyses using
"actual treatment" as an outcome classified as treated only
those patients who actually received a given medication/
treatment. Therefore, both contraindicated patients as
well as those without contraindications were categorized
as untreated.
The data used in these analyses were collected between
December 1999 and December 2003. During this period,
hospitals entered and exited the registry at irregular times,
and remained in the registry for widely varying lengths of
time. Our primary predictor was time in registry, and time
zero was defined as the date of first patient entry for each
hospital. All three optimal treatment outcomes were
examined within each hospital as a function of its length
of time in the registry. Multivariable analyses adjusted
duration in registry by type of facility (academic vs. non-
academic, availability of stroke team) and patient charac-
teristics (age, sex, race/ethnicity, diagnosis, and discharge
disposition). Generalized estimating equations were used
in both univariate and multivariable analyses in order to
adjust for inter-hospital differences and account for clus-
tering of observations at hospitals. Multivariable models
with adjustment for calendar year (with the year 2000 as
a reference) were also examined in sensitivity analysis. All
analyses were performed using SAS (version 8e, SAS Insti-
tute, Cary, NC).
Results
A total of 22,264 patients from 86 hospitals were entered
into the registry. Patients from 27 hospitals that had par-
ticipated in the registry <1 year (n = 2,230) and from nine
hospitals that contributed fewer than 50 patients with
stroke or TIA (n = 413) were excluded. Of the remaining
19,621 patients, 12,263 (62.5%) were diagnosed at dis-
charge with ischemic stroke, 4,038 (20.6%) with TIA,
1,717 (8.7%) with intracerebral hemorrhage, 414 (2.1%)
with subarachnoid hemorrhage, and 1,189 (6.1%) with
conditions other than stroke. Thus, 50 eligible hospitals
contributed 16,301 patients, of whom 12,263 (75.2%)
were diagnosed with ischemic stroke and 4038 (24.8%)
with TIA. Of these patients, 774 (4.7%) died before dis-
charge from the hospital and were excluded from analyses
for which receipt of antithrombotic medication at dis-
charge was the outcome. For receipt of DVT prophylaxis
and antithrombotics within 48 hours, no differences were
observed between analyses that were inclusive or exclusive
of patients who died in hospital. Results are therefore pre-
sented for analyses including all patients. The median
duration of participation in the registry for these hospitals
was 23 months (IQR 16–30). Age, gender, and discharge
disposition were similar across years of registry participa-
tion. Although academic medical centers contributed
more patients in later years (Table 1), there was no signif-
icant difference in the median time spent in registry
between the two groups (22 months for non-academic
hospitals compared to 24 months for academic hospitals,
p = 0.47).
Receipt of antithrombotic medication within 48 hours of 
arrival
Overall, 15,181 patients (93.1%) were optimally treated
with antithrombotic medications within 48 h of hospital
admission. The majority of these (91.8% of all patients)
received antithrombotic medication or thrombolysis.
Valid contraindications (primarily related to risk of bleed-
ing or terminal illness) were cited for an additional 1.4%,
and 6.8% neither received nor had a documented con-
traindication to antithrombotic treatment. In the first
quartile of participation 92.5% were optimally treated.
Longer time spent in registry was associated with
increased rates of in-hospital antithrombotic use (Figure
2; Table 2). Time in registry continued to be significantly
associated with rates of treatment even when adjusted for
calendar year (p = 0.0005, results not shown). In an anal-
ysis ignoring contraindications, actual treatment also
improved with duration of participation (Table 2).BMC Neurology 2006, 6:20 http://www.biomedcentral.com/1471-2377/6/20
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DVT prophylaxis within 48 hours of arrival
Because DVT prophylaxis is generally not necessary in
patients diagnosed with TIA, only the 12,263 patients
diagnosed with ischemic stroke were included in analyses
using optimal treatment for DVT as an outcome. During
the period of observation, 10,067 (82.1%) were optimally
treated: 5,623 patients (45.9% of all 12,263 patients) who
received DVT prophylaxis, and 4,444 (36.2% of all
patients) who were documented as not requiring treat-
ment. Thus, 2196 (17.9%) were not treated and had no
documented reason for this. In the first three months of
registry participation, only 77.1% were optimally treated.
Increased duration of participation in registry was associ-
ated with higher rates of optimal treatment (Figure 2;
Table 2). In a separate multivariable model including cal-
endar year, duration in registry was marginally signifi-
cantly associated with increased optimal treatment rates
(p = 0.06, results not shown). There was no change in
actual receipt of DVT prophylaxis (Table 2), so improve-
ment was likely related to either increased early ambula-
tion or improved documentation.
Antithrombotic use at discharge
Overall, 14,151 patients (91.1% of the 15,527 patients
who survived to discharge) were optimally treated with
antithrombotic medications at discharge, either receiving
Table 2: Duration of Registry Participation as a Predictor of Care
Univariate Analysis Multivariable Analysis‡
Quality Measure Year 1 (n = 
7879) N (%)
Year 2 (n = 
5734) N (%)
Year 3 (n = 
2313) N (%)
Year 4 (n = 
375) N (%)
P value* OR§ 95% CI P value*
Optimal Treatment (those who received therapy or had valid contraindication)
Antithrombotic therapy 
within 48 hours
7244 (91.9) 5365 (93.6) 2214 (95.7) 358 (95.5) 0.001 1.11 (1.04–1.20) 0.003
DVT prophylaxis within 48 
hours†
4607 (76.4) 3595 (85.0) 1596 (92.7) 269 (94.7) 0.01 1.19 (1.02–1.40) 0.03
Antithrombotic medication 
at discharge**
6502 (86.8) 5146 (94.5) 2148 (96.5) 355 (98.1) <0.0001 1.46 (1.24–1.71) <0.0001
Actual Treatment (those who actually received therapy)
Antithrombotic therapy 
within 48 hours
7154 (90.8) 5284 (92.2) 2174 (94.0) 349 (93.1) 0.03 1.06 (0.99–1.14) 0.08
DVT prophylaxis within 48 
hours†
2516 (41.7) 2015 (47.7) 923 (53.6) 169 (59.5) 0.85 0.94 (0.75–1.18) 0.62
Antithrombotic medication 
at discharge**
6236 (83.2) 4877 (89.6) 2026 (91.0) 332 (91.7) 0.003 1.20 (1.06–1.36) 0.005
* Both univariate and multivariate analyses were performed using GEE to adjust for hospital differences
** Excludes patients who died in-hospital (n = 774)
† Analyses included only ischemic stroke patients (n = 12,263)
‡ Adjusted for age, gender, race, type of facility, diagnosis, presence of stroke team, discharge disposition
§Change in outcome for each 6-months in registry
Table 1: Demographic Characteristics by Hospital Years in Registry
Characteristic Total (n = 16301) Year 1 (n = 7879) Year 2 (n = 5734) Year 3 (n = 2313) Year 4 (n = 375)
Age, mean(sd) 71.8 (13.6) 72.1 (13.5) 71.8 (13.6) 71.2 (13.6) 72.0 (13.5)
Female, N(%) 9071 (55.7) 4390 (55.7) 3200 (55.8) 1271 (55.0) 210 (56.0)
Ethnicity, N(%)
Non-Hispanic 
white
13475 (82.7) 6369 (80.8) 4930 (86.0) 1862 (80.5) 314 (83.7)
African-American 2201 (13.5) 1163 (14.8) 611 (10.7) 372 (16.1) 55 (14.7)
Asian/Pacific 
Islander
113 (0.7) 74 (0.9) 26 (0.5) 10 (0.4) 3 (0.8)
Hispanic 123 (0.8) 68 (0.9) 30 (0.5) 25 (1.1) 0 0.0
Other/unknown 389 (2.4) 205 (2.6) 137 (2.4) 44 (1.9) 3 (0.8)
Academic hospital, 
N(%)
10255 (62.9) 4472 (56.8) 3579 (62.4) 1829 (79.1) 375 (100.0)
Ischemic stroke, N(%) 12263 (75.2) 6028 (76.5) 4229 (73.8) 1722 (74.5) 284 (75.7)
Discharged home, 
N(%)
8397 (51.5) 3884 (49.3) 2990 (52.2) 1307 (56.5) 216 (57.6)BMC Neurology 2006, 6:20 http://www.biomedcentral.com/1471-2377/6/20
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them (86.8% of 15,527 patients) or having a valid con-
traindication (4.4%). A total of 1,376 patients (8.9%) did
not receive any antithrombotic medication, and had no
documented reason for non-treatment. Duration of regis-
try participation was associated with the increased use,
increasing steadily from 84.6% in the first three months of
participation (Figure 2; Table 2). This association even
persisted in multivariable analysis that adjusted for calen-
dar year (p = 0.01). Ignoring contraindications, actual
treatment also increased with duration of participation
(Table 2).
Because the hospitals that remained in the registry the
longest period of time were predominantly academic and
this could bias trends, additional analyses were performed
excluding academic hospitals. No significant changes in
the results were observed (data not shown).
Discussion
Among a large sample of hospitals from across the U.S.,
three evaluated measures of quality of care for ischemic
stroke and TIA all indicated suboptimal treatment ini-
tially, but improved after implementation of a web-based
registry. Improvements began in the first year but contin-
ued with longer participation (Figure 2). For use of anti-
thrombotic medications within 48 h and at discharge,
improvements were due to increases in use and were inde-
pendent of calendar year, suggesting that they were not
attributable to broader secular trends in usage but truly
associated with registry participation. For DVT prophy-
laxis, improvements in optimal treatment measures could
not be attributed to actual treatment and may have been
due to better documentation or early ambulation.
Although changes in DVT prophylaxis were dramatic in
univariate analysis (Figure 2; Table 2), there were major
differences between hospitals and the association was
weaker after adjustment and insignificant when calendar
year was included in the model.
One of the major strengths of our study was our ability to
measure change over time within individual hospitals,
rather than relying on aggregated data at different points
in time as previous studies have done. However, given
that hospitals voluntarily participating in the registry were
likely to be interested in improving the quality of stroke
care, our results may have been influenced by selection
bias. Although the registry was likely to have played an
important role in quality-improvement efforts, we have
no systematic knowledge of, and therefore could not
adjust for, additional hospital-level interventions that
might have contributed to improvement. In fact, other
studies have shown that individualized feedback is neces-
sary to produce a substantial impact from registry data
[17,18]. Thus, it is impossible to attribute the improve-
ments in care solely to registry participation as opposed to
other simultaneous interventions. Nonetheless, our study
demonstrates that it is feasible to significantly improve
stroke treatment over a relatively short period of time.
There are several other limitations to our study. By the
very nature of registry participation, we have no control
hospitals. Comparison of these results with data collec-
tion from a sample of hospitals with personnel unaware
that care is being monitored would provide stronger sup-
port for the impact of the registry but may be very difficult
to generate. Also, broader national trends in stroke care
may have influenced outcomes regardless of registry par-
ticipation. However, improvements with antithrombotic
use were not explained by secular trends since they per-
sisted after adjustment for calendar year. A randomized
trial of registry implementation with continuous feedback
to hospitals and physicians would provide the only incon-
trovertible data of efficacy. Given the potential impact of
registries in improving adherence to best practices and,
thus, reducing the risk of in-hospital complications and
recurrent stroke, such a trial is clearly justified from a pub-
lic health perspective.
Of the 50 hospitals included in these analyses, half were
academic institutions. While these hospitals made up the
bulk of the cohort in the last year of data collection, there
was no significant difference overall in the length of time
that academic hospitals participated in the registry com-
pared to non-academic hospitals, and results did not
change appreciably when analyses were performed on
Percentage of patients optimally treated with antithrombotic  medications within 48 h (gray hashed line), DVT prophylaxis  (black hashed line), or antithrombotic medications at dis- charge (black solid line) by quarter of participation in the reg- istry Figure 2
Percentage of patients optimally treated with antithrombotic 
medications within 48 h (gray hashed line), DVT prophylaxis 
(black hashed line), or antithrombotic medications at dis-
charge (black solid line) by quarter of participation in the reg-
istry. Adherence to all three quality-improvement indicators 
improved with duration of participation in the registry.
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non-academic hospitals only. In addition, while hospitals
signed a contract agreeing to enroll all stroke and TIA
admissions during the duration of their participation, no
system was in place to monitor whether or not this did, in
fact, occur. Selective entry of patients into the registry
potentially could have biased the results of the study.
Another shortcoming of our study was a lack of knowl-
edge as to why hospitals chose to withdraw from the reg-
istry once enrolled, or what factors might have
contributed to continued participation over time. Data
from the final year analyzed must be interpreted with cau-
tion, given that only a small number of hospitals
remained in the registry for this period, and these hospi-
tals may represent a biased sample of those institutions
most dedicated to quality improvement. Lastly, the
median catchment area for the included hospitals is in
excess of 330,000, and results therefore may not be gener-
alizable to smaller hospitals in rural areas. 
Conclusion
Although voluntary disease registries have limitations due
to sampling and limited oversight of data quality, they
have been a major source of important health services and
outcomes research in other disease areas. For example,
The National Registry of Myocardial Infarction, a large
voluntary web-based registry for acute myocardial infarc-
tion, has been the source of data for more than 30 major
publications [19]. It has also been a source of data upon
which hospitals have based quality-improvement inter-
ventions [20]. Other voluntary registries in diverse disease
areas have also been the source of important research and
the basis of quality-improvement interventions [21,22].
Ethos and "Get with the Guidelines" [12], a similar volun-
tary registry, may provide such support for those studying
or caring for patients with stroke. Using data from Ethos,
we have shown that, in a large cohort of patients with
stroke or TIA, three targeted quality-improvement meas-
ures improved among participating hospitals. Although
the changes could be attributed to interventions other
than the registry, these findings demonstrate the potential
for hospital-level interventions to improve care for
patients with stroke and TIA. Stroke registry use is likely to
increase rapidly since accreditation of hospitals as primary
stroke centers by the Joint Commission on Accreditation
of Healthcare Organizations requires quality-of-care
measurements that will necessitate systematic collection
of more detailed data [14]. Our study suggests that partic-
ipation in such a registry, along with complementary hos-
pital-wide interventions, may encourage improvement in
quality of stroke care, and our baseline data, which are
consistent with other studies [7], suggest that such
improvement is necessary.
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